ECSP003508A - Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas - Google Patents
Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticasInfo
- Publication number
- ECSP003508A ECSP003508A EC2000003508A ECSP003508A ECSP003508A EC SP003508 A ECSP003508 A EC SP003508A EC 2000003508 A EC2000003508 A EC 2000003508A EC SP003508 A ECSP003508 A EC SP003508A EC SP003508 A ECSP003508 A EC SP003508A
- Authority
- EC
- Ecuador
- Prior art keywords
- citrate
- octan
- azobiciclo
- amina
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title abstract 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una forma polimorfa cristalina individual del citrato de (2S,3S) -(metoxi-5-t-buti!fenilmetil-2-difenilmetil-I-azobiciclo[2,2,2) octan-3-amina (citrato monohidrato) y su composición farmacéutica. La composición farmacéutica de la forma polimorfa si el citrato monohidrato tiene la estabilidad necesaria para una formulación para tratar la emesis. La administración de esta composición farmacéutica es una forma de dosificación oral de liberación inmediata, preferiblemente en forma de comprimido o cápsula, o intravenosa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13699299P | 1999-06-01 | 1999-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003508A true ECSP003508A (es) | 2002-02-25 |
Family
ID=22475338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2000003508A ECSP003508A (es) | 1999-06-01 | 2000-06-01 | Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas |
Country Status (48)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2554346C (en) * | 2004-01-30 | 2009-11-17 | Pfizer Products Inc. | Parenteral formulations comprising a beta-cyclodextrin and a preservative |
| MXPA06008648A (es) * | 2004-01-30 | 2006-09-04 | Pfizer Prod Inc | Composiciones farmaceuticas de antagonistas del receptor de neuroquinina y ciclodextrina y metodos para una tolerancia mejorada en el sitio de inyeccion. |
| CN1913893A (zh) | 2004-01-30 | 2007-02-14 | 辉瑞产品有限公司 | 改善麻醉恢复的nk-1受体拮抗剂 |
| BRPI0507334A (pt) * | 2004-02-02 | 2007-07-03 | Pfizer Prod Inc | processo para a preparação de -1(2s,3s)-2-benzidril-n-(5-terc-butil-2-metoxibenzila)q uinuclidin-3-amina |
| CA2905542C (en) * | 2013-03-15 | 2022-05-03 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
| CN110577522B (zh) * | 2018-06-07 | 2022-12-27 | 东莞市东阳光动物保健药品有限公司 | 马罗匹坦柠檬酸盐新晶型及其制备方法 |
| CN112979639B (zh) * | 2019-12-16 | 2025-08-08 | 凯默斯医药科技(上海)有限公司 | 一种马罗皮坦新晶型及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE9290063U1 (de) * | 1991-05-31 | 1994-02-24 | Pfizer Inc., New York, N.Y. | Chinuclidin-Derivate |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
-
2000
- 2000-05-08 US US09/566,307 patent/US6255320B1/en not_active Expired - Lifetime
- 2000-05-17 HN HN2000000077A patent/HN2000000077A/es unknown
- 2000-05-18 UA UA2001118214A patent/UA66925C2/uk unknown
- 2000-05-18 ES ES00925528T patent/ES2199825T3/es not_active Expired - Lifetime
- 2000-05-18 EP EP00925528A patent/EP1181290B1/en not_active Expired - Lifetime
- 2000-05-18 OA OA1200100318A patent/OA11956A/en unknown
- 2000-05-18 MX MXPA01012325A patent/MXPA01012325A/es unknown
- 2000-05-18 TR TR2001/03473T patent/TR200103473T2/xx unknown
- 2000-05-18 BR BR0011094-9A patent/BR0011094A/pt not_active Application Discontinuation
- 2000-05-18 SI SI200030161T patent/SI1181290T1/xx unknown
- 2000-05-18 PL PL00352716A patent/PL196046B1/pl not_active IP Right Cessation
- 2000-05-18 HU HU0201301A patent/HUP0201301A3/hu unknown
- 2000-05-18 PT PT00925528T patent/PT1181290E/pt unknown
- 2000-05-18 AP APAP/P/2001/002349A patent/AP2001002349A0/en unknown
- 2000-05-18 WO PCT/IB2000/000665 patent/WO2000073304A1/en not_active Ceased
- 2000-05-18 EA EA200101108A patent/EA003731B1/ru active Protection Beyond IP Right Term
- 2000-05-18 AU AU44248/00A patent/AU767334B2/en not_active Expired
- 2000-05-18 EE EEP200100656A patent/EE200100656A/xx unknown
- 2000-05-18 CA CA002372238A patent/CA2372238C/en not_active Expired - Lifetime
- 2000-05-18 CZ CZ20014269A patent/CZ295819B6/cs not_active IP Right Cessation
- 2000-05-18 AT AT00925528T patent/ATE244239T1/de not_active IP Right Cessation
- 2000-05-18 DK DK00925528T patent/DK1181290T3/da active
- 2000-05-18 KR KR10-2001-7015494A patent/KR100476606B1/ko not_active Expired - Fee Related
- 2000-05-18 SK SK1733-2001A patent/SK285820B6/sk not_active IP Right Cessation
- 2000-05-18 CN CNB008082782A patent/CN1146565C/zh not_active Expired - Lifetime
- 2000-05-18 HR HR20010904A patent/HRP20010904A2/hr not_active Application Discontinuation
- 2000-05-18 JP JP2001500629A patent/JP3830816B2/ja not_active Expired - Lifetime
- 2000-05-18 NZ NZ515349A patent/NZ515349A/xx unknown
- 2000-05-18 IL IL14640600A patent/IL146406A0/xx not_active IP Right Cessation
- 2000-05-18 YU YU81101A patent/YU81101A/sh unknown
- 2000-05-18 DE DE60003679T patent/DE60003679T2/de not_active Expired - Lifetime
- 2000-05-23 PA PA20008496101A patent/PA8496101A1/es unknown
- 2000-05-26 CO CO00039195A patent/CO5170463A1/es not_active Application Discontinuation
- 2000-05-26 TW TW089110206A patent/TWI285204B/zh not_active IP Right Cessation
- 2000-05-29 UY UY26176A patent/UY26176A1/es not_active Application Discontinuation
- 2000-05-30 MY MYPI20002409A patent/MY133508A/en unknown
- 2000-05-30 PE PE2000000520A patent/PE20010209A1/es not_active Application Discontinuation
- 2000-05-30 AR ARP000102663A patent/AR033331A1/es active IP Right Grant
- 2000-05-31 SV SV2000000093A patent/SV2001000093A/es unknown
- 2000-05-31 TN TNTNSN00120A patent/TNSN00120A1/fr unknown
- 2000-05-31 DZ DZ000101A patent/DZ3050A1/xx active
- 2000-05-31 MA MA25997A patent/MA26742A1/fr unknown
- 2000-05-31 GT GT200000087A patent/GT200000087A/es unknown
- 2000-06-01 EC EC2000003508A patent/ECSP003508A/es unknown
-
2001
- 2001-11-28 ZA ZA200109775A patent/ZA200109775B/en unknown
- 2001-11-30 NO NO20015848A patent/NO20015848L/no not_active Application Discontinuation
- 2001-12-10 BG BG106204A patent/BG65240B1/bg unknown
-
2007
- 2007-03-27 CY CY2007011C patent/CY2007011I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036768A1 (es) | Formas de administracion de propiverina o sus sales farmaceuticamente aceptables con liberacion prolongada de la sustancia activa | |
| CL2009001682A1 (es) | Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). | |
| AR022008A1 (es) | Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento | |
| ES2181055T3 (es) | Formulaciones galenicas que contienen antagonistas de opiaceos. | |
| DK0954314T3 (da) | Doseringsformer til bedring af mandlig erektionsdefekt | |
| BR0206695A (pt) | Formas de dosagem de epotilonas para administração oral | |
| EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
| BR0114100A (pt) | Formulações de liberação controlada para administração oral | |
| ECSP003508A (es) | Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas | |
| ECSP003538A (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2.] oct-3-ilamina y sus composiciones farmaceuticas | |
| AR003434A1 (es) | Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas. | |
| UY28457A1 (es) | Nueva composición | |
| MY141008A (en) | Oral formulations of deoxypeganine and their uses | |
| UY26177A1 (es) | Polimorfos de un citrato de azobiciclo (2.2.2) oct-3- ilamina cristalino y sus composiciones farmacéuticas. | |
| HUP0400495A2 (hu) | Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény | |
| ATE302010T1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
| IT1293835B1 (it) | Composizioni farmaceutiche orali in forma solida a cessione modulata contenenti nicorandil e procedimento per la loro preparazione | |
| ECSP003510A (es) | Polimorfos de un citrato de azobiciclo (2,2,2) oct - 3 - ilamina cristalino y sus composiciones farmaceuticas | |
| GT200000104A (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo 2.2.2 oct - 3 - ilamina y sus composicionesfarmaceuticas. | |
| DE50311479D1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung | |
| MY145885A (en) | Controlled release formulations for oral administration | |
| UY27122A1 (es) | Una composición farmacéutica que comprende de 2 a 4 mg de 5-(a-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona | |
| UY27771A1 (es) | Procedimiento para preparar composiciones farmacéuticas de 2 a 8 mg de 5- (4-(2-(n-metil.n(2-piridilo) amino) etoxi) bencilo) tiazolidino-2,4-diona. | |
| ECSP982396A (es) | Composiciones que contienen tetrahidrolipstatina |